NCT04409132View on ClinicalTrials.gov

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

April 2, 2021

Study Completion Date

April 2, 2021

Conditions
End Stage Renal Disease
Interventions
DRUG

Triferic

Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

All Listed Sponsors
lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT04409132 - Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus. | Biotech Hunter | Biotech Hunter